Invest in the Future of Molecular Diagnostics
Genedrive plc: Innovating point-of-care genetic testing to transform global healthcare.
Latest news
Blogs
Financial Reports
PR
View all
Filter by
Corporate Governance
On 4 July 2018, the Board of genedrive plc decided to apply The QCA Corporate Governance Code (2018 edition) (the QCA Code).
As a result of deciding to apply the QCA Code, the corporate governance principles which now apply to us are those contained in the QCA Code.
These principles, how we apply them and references to where further information can be found here
Shareholders
Genedrive shares are quoted and traded on the AIM market of the London Stock Exchange.
Authorised Share Capital: No authorised maximum number of shares are required. There are no shares held in treasury and there are no restrictions on transfer.
Issued Share Capital: The total number of genedrive plc ordinary shares of 1.5p each in issue is 543,141,481.
Number of AIM securities not in public hands is 6,244,877 or 1.15%.
Text updated: 15/08/2024
Key financial metrics
Investor contacts
Financial PR and Investor Relations
Paul McManus and Anna Dunphy Walbrook PR Ltd 4 Lombard Street London
EC3V 9HD
Tel: +44 (0) 20 7933 8780
Email: genedrive@walbrookpr.com
Paul McManus and Anna Dunphy Walbrook PR Ltd 4 Lombard Street London
EC3V 9HD
Tel: +44 (0) 20 7933 8780
Email: genedrive@walbrookpr.com
Investor alerts
Subscribe to our update alert service and receive all press releases, results and other key messages as soon as they become available.
trusted by
